Zacks: Analysts Anticipate Cambrex Co. (CBM) Will Announce Earnings of $0.59 Per Share

Share on StockTwits

Brokerages expect Cambrex Co. (NYSE:CBM) to post earnings per share (EPS) of $0.59 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Cambrex’s earnings. The lowest EPS estimate is $0.55 and the highest is $0.63. Cambrex reported earnings per share of $0.55 during the same quarter last year, which indicates a positive year over year growth rate of 7.3%. The firm is scheduled to announce its next earnings results on Tuesday, November 6th.

On average, analysts expect that Cambrex will report full-year earnings of $2.95 per share for the current fiscal year, with EPS estimates ranging from $2.91 to $2.99. For the next fiscal year, analysts anticipate that the firm will post earnings of $3.17 per share, with EPS estimates ranging from $2.91 to $3.32. Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Cambrex.

Cambrex (NYSE:CBM) last announced its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported $0.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.05. Cambrex had a net margin of 20.75% and a return on equity of 22.32%. The company had revenue of $152.05 million during the quarter, compared to analysts’ expectations of $132.78 million. During the same period in the previous year, the company earned $0.76 EPS. The business’s quarterly revenue was up 13.0% compared to the same quarter last year.

Several equities analysts recently weighed in on the stock. ValuEngine upgraded shares of Cambrex from a “sell” rating to a “hold” rating in a report on Friday, July 6th. Jefferies Financial Group assumed coverage on shares of Cambrex in a report on Tuesday, September 25th. They set a “buy” rating and a $75.50 target price on the stock. Finally, Zacks Investment Research upgraded shares of Cambrex from a “hold” rating to a “strong-buy” rating and set a $73.00 target price on the stock in a report on Wednesday, August 8th. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Cambrex presently has a consensus rating of “Buy” and an average price target of $69.50.

In related news, Director Ilan Kaufthal sold 5,500 shares of Cambrex stock in a transaction on Monday, August 6th. The shares were sold at an average price of $62.38, for a total transaction of $343,090.00. Following the transaction, the director now owns 54,084 shares in the company, valued at approximately $3,373,759.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Steven M. Klosk sold 55,000 shares of Cambrex stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $66.30, for a total transaction of $3,646,500.00. Following the transaction, the chief executive officer now owns 138,328 shares in the company, valued at approximately $9,171,146.40. The disclosure for this sale can be found here. Insiders have sold a total of 298,760 shares of company stock worth $18,730,127 in the last 90 days. Company insiders own 2.42% of the company’s stock.

Several large investors have recently bought and sold shares of CBM. BlackRock Inc. lifted its holdings in Cambrex by 8.7% in the 2nd quarter. BlackRock Inc. now owns 4,624,250 shares of the biotechnology company’s stock worth $241,849,000 after buying an additional 370,806 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Cambrex by 3.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,471,966 shares of the biotechnology company’s stock worth $76,982,000 after buying an additional 54,475 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in Cambrex by 1.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,420,580 shares of the biotechnology company’s stock worth $74,295,000 after buying an additional 13,858 shares in the last quarter. American Capital Management Inc. lifted its holdings in Cambrex by 6.7% in the 2nd quarter. American Capital Management Inc. now owns 720,476 shares of the biotechnology company’s stock worth $37,681,000 after buying an additional 45,312 shares in the last quarter. Finally, Boston Partners lifted its holdings in Cambrex by 3.2% in the 2nd quarter. Boston Partners now owns 699,286 shares of the biotechnology company’s stock worth $36,572,000 after buying an additional 21,399 shares in the last quarter.

Shares of NYSE CBM traded up $0.77 during trading on Tuesday, hitting $54.02. 13,861 shares of the company traded hands, compared to its average volume of 372,871. The stock has a market capitalization of $1.77 billion, a PE ratio of 17.04, a P/E/G ratio of 1.89 and a beta of 2.44. Cambrex has a 1 year low of $42.55 and a 1 year high of $69.43.

Cambrex Company Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.

See Also: Diversification

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply